Recent Company News

• 04:15 PM ET Apr 28, 2025
  

  GENFIT: late-breaking Ph.2 data for elafibranor in PSC to be presented by Ipsen at EASL Congress 2025 (€3.38, 0.00)

• 04:15 PM ET Apr 24, 2025
  

  GENFIT reports FY net income €1.5M vs FactSet €7.0M [5 est, (€16.2)-34.9M] (€3.22, 0.00)

• 11:15 AM ET Apr 10, 2025
  

  StreetAccount Summary - US unusual volume traders

• 03:15 AM ET Mar 27, 2025
  

  GENFIT reinstated buy at Van Lanschot Kempen; prior rating was buy (€3.28, 0.00)

• 06:44 AM ET Mar 21, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 05:20 PM ET Mar 20, 2025
  

  GENFIT announces completion of royalty financing agreement with HCRx and results of repurchase offer to 2025 OCEANEs holders (€3.32, 0.00)

• 04:47 PM ET Feb 27, 2025
  

  GENFIT reports FY revenue €67.0M vs FactSet €91.8M [6 est, €43.9-119.4M] (€3.47, 0.00)

• 02:40 AM ET Feb 21, 2025
  

  GENFIT announces preliminary results of the repurchase offer to 2025 OCEANEs holders (€3.65, 0.00)

• 04:20 PM ET Feb 14, 2025
  

  GENFIT announces amendment of the final terms of the dual proposal to the 2025 OCEANEs holders (€3.88, 0.00)

• 01:31 AM ET Feb 10, 2025
  

  GENFIT announces final terms for dual proposal to the 2025 OCEANEs holders (€3.75, 0.00)